News
REVBW
0.0099
+1.02%
0.0001
Revelation Biosciences Adopts Stockholder Rights Protection Plan
TipRanks · 9h ago
Weekly Report: what happened at REVB last week (0706-0710)?
Weekly Report · 20h ago
Revelation Biosciences' Board Implements Shareholder Rights Plan, Declares Dividend Distribution Of One Right For Each Outstanding Common Stock
Benzinga · 3d ago
Revelation Biosciences issues stockholder rights dividend under new poison pill plan
PUBT · 3d ago
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Barchart · 3d ago
Weekly Report: what happened at REVB last week (0629-0703)?
Weekly Report · 07/06 10:21
Weekly Report: what happened at REVB last week (0622-0626)?
Weekly Report · 06/29 10:16
Revelation Biosciences Updates Executive Contracts, Shareholder Actions
TipRanks · 06/24 21:19
Revelation Biosciences shareholders approved board authority for reverse stock split range up to 1-for-250
PUBT · 06/24 20:48
Weekly Report: what happened at REVB last week (0615-0619)?
Weekly Report · 06/22 10:25
Weekly Report: what happened at REVB last week (0608-0612)?
Weekly Report · 06/15 10:26
Weekly Report: what happened at REVB last week (0601-0605)?
Weekly Report · 06/08 10:22
Revelation Biosciences adds two new members to AKI Advisory Board
TipRanks · 06/01 13:56
Weekly Report: what happened at REVB last week (0525-0529)?
Weekly Report · 06/01 10:26
Weekly Report: what happened at REVB last week (0518-0522)?
Weekly Report · 05/25 10:30
Weekly Report: what happened at REVB last week (0511-0515)?
Weekly Report · 05/18 10:30
Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year
TipRanks · 05/11 13:48
Weekly Report: what happened at REVB last week (0504-0508)?
Weekly Report · 05/11 10:27
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Enovis (ENOV) and Revelation Biosciences (REVB)
TipRanks · 05/08 17:31
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
Benzinga · 05/08 16:05
More
Webull provides a variety of real-time REVBW stock news. You can receive the latest news about Rvltn Bioscnc through multiple platforms. This information may help you make smarter investment decisions.
About REVBW
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).